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Abstract This study determined whether motivational
interviewing-based cognitive behavioral therapy (MI-CBT)
adherence counseling combined with modified directly
observed therapy (MI-CBT/mDOT) is more effective than
MI-CBT counseling alone or standard care (SC) in increasing
adherence over time. A three-armed randomized controlled
48-week trial with continuous electronic drug monitored
adherence was conducted by randomly assigning 204 HIV-
positive participants to either 10 sessions of MI-CBT coun-
seling with mDOT for 24 weeks, 10 sessions of MI-CBT
counseling alone, or SC. Poisson mixed effects regression
models revealed significant interaction effects of intervention
over time on non-adherence defined as percent of doses not-
taken (IRR = 1.011, CI = 1.000–1.018) and percent of doses
not-taken on time (IRR = 1.006, CI = 1.001–1.011) in the
30 days preceding each assessment. There were no significant
differences between groups, but trends were observed for the
MI-CBT/mDOT group to have greater 12 week on-time and
worse 48 week adherence than the SC group. Findings of
modest to null impact on adherence despite intensive inter-
ventions highlights the need for more effective interventions
to maintain high adherence over time.
Resumen Esta investigacio´n determina si la Terapia
Cognitivo-Conductal basada en la Entrevista Motivacional
(MI-CBT) combinada con Terapia de Observacio´n Directa
modificada (MI-CBT/mDOT) es ma´s efectiva que una inter-
vencio´n que solo incluye MI-CBT o el cuidado esta´ndar (SC)
para aumentar la adherencia a medicamento a largo plazo.
Llevamos a cabo un periodo de prueba controlado de tres
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ramas aleatorias por 48 semanas, el cual incluye un seguimi-
ento electro´nico continuo de adherencia a medicamento. Un
total de 204 participantes VIH-positivo fueron aleatoriamente
asignados a 10 sesiones de terapia MI-CBT con mDOT por 24
semanas, 10 sesiones de terapia MI-CBT sola, o SC. Modelos
de regresio´n Poisson de efectos mixtos revelaron efectos
significativos de interaccio´n de la intervencio´n por tiempo en
no-adherencia definida por el porciento de dosis no-tomadas
(IRR = 1.011, CI = 1.000–1.018) y el porciento de dosis
no-tomadas a tiempo (IRR = 1.006, CI = 1.001–1.011) a 30
dı´as antes de cada evaluacio´n. No hubo diferencias signifi-
cantes entre grupos, pero el grupo de MI-CBT/mDOT
tubo tendencia a tener mejor adherencia a tomar el medica-
mento a tiempo a las 12 semanas y peor adherencia a las 48
semanas comparado con el grupo SC. Estos resultados de
efectos nulo-a-modesto en la adherencia a pesar de interven-
ciones intensivas, recalcan la necesidad de tener ma´s interv-
enciones efectivas que ayuden a mantener una alta adherencia
a largo plazo.
Keywords Adherence  HIV/AIDS  ART  Motivational
Interviewing  Directly Observed Therapy
Introduction
Widespread use of antiretroviral therapy (ART) has resul-
ted in significant numbers of patients achieving durable
viral load (VL) suppression and reduced morbidity and
mortality [1, 2]. The benefits of ART are clear [3], however
its initial success and long-term effectiveness are depen-
dent on strict regimen adherence, which is difficult and
often not sustainable over time [4, 5].
Most studies to promote ART adherence have tested cog-
nitive-behavioral techniques for increasing knowledge and
skills for adherence with several demonstrating promise
[6–8]. Some of the most effective trials have combined
motivational interviewing (MI) techniques with cognitive-
behavioral treatment (CBT) techniques to produce compre-
hensive ART adherence counseling interventions [7, 9–12].
Others which have focused on providing external supports for
adherence, like modified directly observed therapy (mDOT),
have also shown some promise [13–16] although null results
and high burden have also been noted [17]. Both approaches
are potentially cost effective [18] and adaptable to a variety of
patients and settings [19, 20], however no studies have
assessed the combined effect of motivational interviewing-
based cognitive behavioral therapy (MI-CBT) counseling and
mDOT approaches. Evidence of whether such a combination
has an additive effect on adherence and clinical outcomes
would inform the allocation of limited resources for adherence
enhancement in community practice.
This paper reports findings from a three arm, randomized
controlled trial that examined whether MI-CBT counseling
combined with mDOT (MI-CBT/mDOT) is more effective
than counseling alone (MI-CBT) or standard care (SC) for
increasing adherence to ART over 48 weeks among HIV-
positive community clinic patients. The secondary aim was
to evaluate intervention effects on suppression of VL.
Methods
Procedures
Data were collected from December 2004 to August 2009 at
six outpatient clinics in Kansas City. Eligible participants
were HIV-positive and were either: starting ART for the first
time; making a change to their regimen; or having self-
reported adherence problems (confirmed by provider docu-
mentation and/or HIV RNA [1,000 copies/mL). Participants
were also[18 years of age and English speaking. Participants
were excluded if they were pregnant, had an acute illness that
would interfere with their ability to participate, did not self-
administer their ART, or did not live within a 70-mile radius of
the project office. Approval for the study was obtained from
the appropriate Institutional Review Boards.
Participants completed the baseline assessment that
included demographic, adherence, psychosocial and medical
variables via Audio Computer Assisted Self Interview and
were randomized on a 1:1:1 ratio. Participants Group random
assignment was stratified by ART naı¨ve/experienced and by
clinic. An adapted version of the Alcohol and Substance Use
Inventory [21] was used to collect data on the frequency and
quantity of substance use. Participants reported their fre-
quency of binge drinking over the past 30 days and their use
of drugs (i.e., illicit, prescription or over the counter drugs
taken in excess of the directions) from seven specific drug
classifications (e.g., marijuana, cocaine, opiates, and
amphetamines) over the past 3 months. Binge drinking was
defined as having six or more alcoholic drinks during a single
drinking occasion. The Center for Epidemiologic Studies
Depression Scale (CES-D; [22]) was used to assess depres-
sive symptoms. Intervention and data collection activities
were completed by different project staff.
Each participant was given an electronic drug monitor
(EDM; http://www.aardex.ch) to be used continuously
throughout the study to track adherence. When participants
were on more than one ART medication, we monitored
adherence to the drug with the most complex dosing
schedule or to the drug that was expected to have the most
severe side effects if dosing schedules were identical for all
medications. Participants continued to receive routine
medical care and were scheduled for monthly EDM
downloads and follow-up assessments at 12, 24, 36,
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48 weeks. Participants were provided up to $165 for
completion of assessment visits (i.e., $20 at the baseline, 12
and 36 week visits; $40 at the 24 week visit; and $65 at the
48 week visit). To increase identification with the study
and retention, participants were also offered attractive
Project MOTIV8 logo items (e.g., t-shirts and water bot-
tles) and a study completion certificate.
Standard Care (SC)
Participants assigned to SC received medical care and
adherence counseling as usual from their clinic providers.
A multi-modal assessment (i.e., randomly selected conve-
nience subsample of medical record abstractions, provider
surveys, and patient surveys) was employed to evaluate the
SC delivered by the clinics where the majority (82 %) of
participants received care. We assessed SC recommended
monitoring of patients receiving ART including clinic
visits and laboratory tests at anticipated intervals to assess
effectiveness and safety, side effect monitoring and man-
agement, and continual adherence assessment and coun-
seling [23–25]. Data was collected prior to initiation of
participant recruitment and repeated when the final par-
ticipants were completing the study. No differences
between clinics were noted, however clinic care changed in
accordance with updated recommended guidelines at
approximately the same time at all sites [26].
Motivational Interviewing Based Cognitive Behavioral
Counseling (MI-CBT)
Participants assigned to the MI-CBT and MI-CBT/mDOT
arms received care as usual from their clinic providers and
met with project staff for six face-to-face MI-CBT coun-
seling sessions (weeks 0, 1, 2, 6, 11 and 23) and four
telephone sessions (weeks 4, 9, 15, and 19).
Our MI-CBT intervention included the use of MI; [27]
techniques to increase motivation and confidence for
change as well as the use of cognitive-behavioral approa-
ches delivered in an MI-consistent style to enhance
knowledge and build skills (e.g., self-monitoring, problem-
solving, talking to your doctor) for adherence [28]. On
average, sessions lasted 25 min. Counselors were Master’s
degree level professionals trained and supervised by a
licensed clinical psychologist. Counselors digitally recor-
ded sessions and received ongoing weekly supervision in
which randomly selected session tapes were coded for
fidelity using a 26-item coding scheme adapted from our
prior work [29]. Counselors maintained high fidelity
throughout the study with an average rating of 6.2 (SD = 1)
on an overall summary item (‘‘Overall, how well did the
counselor conduct this session?’’) scored on a 7-point scale
ranging for poor [1] to excellent [7].
Modified Directly Observed Therapy (mDOT)
Participants in the MI-CBT/mDOT intervention arm
received care as usual from their clinic providers, the
MI-CBT counseling described above, and daily mDOT
visits (Monday through Friday) from baseline through
week 16. Visits were tapered at week 17 until they ceased
at week 24. Each mDOT visit (average length 5.2 min)
was conducted at a location and planned dose time that was
most convenient for the participant.
As with participants in the other groups, MI-CBT/
mDOT participants obtained their own ART medications
and kept one medication in the EDM bottle. Their
remaining ART medications were transferred to study staff.
MI-CBT/mDOT participants were always in possession of
a 1-week emergency back-up supply of all of their medi-
cations for use if a visit was missed. At each visit, ingestion
of an ART dose was observed, remaining daily doses were
delivered (weekend doses were delivered on Fridays), and
participants reported on their adherence to all unobserved
ART doses since the last mDOT visit using personal digital
assistants (PDA’s). Initially all of these visits were con-
ducted in person, however due to medication regimen
changes (i.e., more once per day ART), late night dosing
(e.g., efavirenz), and the inclusion of participants who lived
outside of the catchment area, the mDOT protocol was
revised over the course of the study to include in-person as
well as ‘phone contacts’ (participant ingested medication
during a study staff initiated phone call at the predeter-
mined dose time), ‘med delivery’ (meds delivered outside
of target dosing time and participant reported by phone/text
when ingested), and ‘PDA visits’ (meds delivered outside
of target dosing time and participant retrospectively
reported on all unobserved doses using PDA). These
adaptations made our version of mDOT distinct from
others tested in previous studies. During weeks 22 and 23
staff ensured that participants could accurately fill their pill
boxes and then returned all remaining medications to par-
ticipants at the last mDOT visit.
Outcomes Measures
Raw EDM adherence data were cleaned to ensure that no
patient had greater than 100 % adherence in any 24 h
period. Periods where participants were unable to use the
EDM cap due to hospitalization, physician ordered medi-
cation holiday, or incarceration were also excluded. Each
opening was then evaluated to determine whether or not the
dose was ‘on time.’ Cap openings for participants on once
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daily and twice a day dosing schedules were on time if the
opening occurred within ±2 h of the scheduled dosing
time. Summary adherence variables of percent of doses
taken and percent of doses taken on time for the 30 day
period before each assessment visit were then calculated
for each participant.
Study staff abstracted HIV VL from medical records if
they were available, generally within ±30 days of assess-
ment visits, otherwise blood draws were conducted at the
assessment visits. In order to accommodate VL testing
standards over the entire study period, data were dichoto-
mized as undetectable (\400 copies/mL) or detectable
([400 copies/mL).
Dose of Intervention
To explore dose response effects, a variable was con-
structed that reflected how much intervention each partic-
ipant received. Participants in the SC arm were given a ‘‘0’’
as they received no intervention. MI-CBT and mDOT dose
was computed as the percent of possible sessions that were
completed. The final intervention dose variable reflected
the MI-CBT dose for those assigned to the MI-CBT arm
and the sum of the MI-CBT and mDOT doses for those
assigned to the MI-CBT/mDOT arm.
Statistical Methods
Primary and secondary outcomes were analyzed using an
intention-to-treat analysis. Both percent taken and percent on
time adherence outcomes violated Mauchly’s test of sphe-
ricity and evidence highly negatively skewed distributions
making our planned least squares regression approach
problematic. Based on recommendations of Gardner [30] for
managing rate data, Poisson mixed effects regression models
were fit to assess effects of intervention group over time
(intervention group and observation period as fixed effects)
clustered within individual (participants as a random effect)
on rate of adherence. To better meet the assumptions of the
Poisson mixed model, data were reverse coded by subtract-
ing percent taken adherence rate from 100 to create a percent
of doses not-taken outcome. The same was done to produce a
percent of doses not-taken on time outcome. The Poisson
mixed effects model provides an appropriate mechanism for
handling repeated measures rate data while allowing for the
inclusion of available data from participants who had miss-
ing evaluation time points. This was an additional advantage
as we had partial missing data from 42 participants. Analyses
were conducted using STATA 11.0 SE (StataCorp LP,
College Station TX) to derive full maximum-likelihood and
variance estimates with model assumptions confirmed
through the analysis of residuals. For all models, the likeli-
hood ratio test was used for comparison of nested models
(random intercept and random coefficients models). The
regression values are reported as incidence rate ratios (IRR;
predicted values that are natural logarithms of relative risk)
modeling non-adherence.
Additionally, models were fit to explore the effect of
dose of intervention on non-adherence. Participants
assigned to the SC group were not included in the dose
analyses. In order to explore the effect of increasing dose
of intervention, dose was categorized into quintiles (from
lowest to highest) for analyses. As with the other outcomes,
mixed effects Poisson models were fit.
A logistic mixed effect regression model was fit to
evaluate suppression of VL to undetectable as a function of
intervention group while controlling for observation per-
iod. Odds ratios (OR) are reported for undetectable VL
(binary data) using robust standard errors to provide con-
servative estimates of statistical significance.
Results
Recruitment and Attrition
Of the 1,502 patients screened for eligibility, 1,187 (79 %)
did not meet study eligibility criteria, because they were
not switching medications, not on medications, not expe-
riencing adherence problems, were pregnant, or had an
opportunistic infection (see Fig. 1). Of the 315 who met
eligibility criteria, 97 (31 %) were approached but declined
to participate. The primary reasons for refusal were lack of
interest in research, being too busy, and anticipating an out
of town move.
Attrition over the 48 week study was 16.7 % and did not
differ by study arm. A total of 901 (88 % of total possible)
assessment sessions were completed. Data were collected
from all 204 participants at baseline, 181 at 12 and
24 weeks, 165 at 36 weeks, and 170 participants at week
48. Sociodemographic characteristics of participants with
complete self-report data (75 %), those who missed a sin-
gle assessment (9 %), and those who missed two or more
assessments (16 %) did not differ (all ps [ .10).
Participant Characteristics and Evaluation
of Randomization
Participants ranged in age from 18 to 65, 47 % were het-
erosexual, and 91 % had stable housing (see Table 1). At
baseline, participants had been diagnosed with HIV for an
average of 8 years, and most were on once (n = 108,
53 %) or twice (n = 89, 44 %) daily ART regimens with a
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small percentage (n = 7, 3 %) on a thrice per day regimen.
There were no baseline differences between groups on any
sociodemographic, regimen, or predictor variables (see
Table 1; all ps [ .10).
Uptake of the Interventions
A total of 1,170 (77 % of the total possible) MI-CBT
counseling sessions were completed by participants in the
MI-CBT and MI-CBT/mDOT study arms. The average
number of counseling sessions was similar between par-
ticipants in the MI-CBT (8.40, SD = 2.7) and MI-CBT/
mDOT (8.43, SD = 2.9) arms (p = .94).
A total of 4,139 (61 % of total possible) mDOT visits
were completed. Of the total, 1,927 mDOT visits were
completed in person, 1,324 were completed via phone, 764
visits were med delivery, and 124 were PDA visits. The
average rate of completion in the MI-CBT/mDOT arm was
60 (SD = 28) of the 98 total possible mDOT visits.
A Poisson mixed effects regression model revealed that
average non-adherence was not significantly different for
participants who received the majority of their mDOT ses-
sions in person or via phone (IRR = 1.46, SE = .85, 95 %
CI =
.47–4.57, p = .51). Average dose of intervention was 76.4
(SD = 24.0) for participants in the MI-CBT arm and 148.7
(SD = 52.7) for MI-CBT/mDOT participants.
Missing Data
Because EDM data is recorded continuously and stored,
prior adherence data can be collected at any point that the
cap is available. For this reason we were sometimes able to
capture EDM adherence data that coincided with a missed
assessment visit. For week 12, we had 91 % of all possible
EDM data, 89 % at week 24, 86 % at week 36, and 81 % at
week 48. Comparison of participants with complete versus
incomplete EDM data identified no significant differences
Fig. 1 Study flowchart
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in sociodemographic characteristics. In total, 24 % of VL
data across all assessment visits were missing. Specifically,
we had no missing VL data at baseline, 22 % missing at
12 weeks, 23 % missing at 24 weeks, 41 % missing at
36 weeks, and 34 % missing at 48 weeks.
Evaluation of Intervention Effects
Table 2 summarizes mean adherence for both percent of
doses taken and percent of doses taken on time at each
assessment point and by group. Analyses were based on the
intent-to-treat sample of 204 participants. Of these, 14 sub-
jects had insufficient data over time to be included in the
analyses exploring intervention effects (i.e., data for fewer
than three of the four time points). Four Poisson mixed
regression models were fit to assess non-adherence. Models
were fit to test the effect of intervention group and obser-
vation period on non-adherence defined as percent of doses
not-taken (Model 1) and percent of doses not-taken on time
(Model 2) in the 30 days preceding each assessment visit
(Table 3). Results of Model 1 revealed a statistically sig-
nificant, albeit small, interaction effect of intervention over
time (IRR 1.011, 95 % CI = 1.004–1.018, p = .003) on
non-adherence indicating that the change in adherence over
time differed between the study groups. Model 2 had similar
findings to Model 1 with a statistically significant, yet small,
interaction effect between intervention group and observa-
tion period (IRR = 1.006, 95 % CI = 1.001–1.011, p =
.015). In both models, neither the intervention group nor
observation period main effects were significant predictors
of non-adherence; however, a trend emerged for the main
effect of intervention group on percent of doses not-taken
on time (IRR .782, 95 % CI = .594–1.029, p = .079).
Inspection of the means in Table 2 revealed a cross-over in
adherence trends over time for both percent of doses and
percent of doses on time such that the MI-CBT/mDOT
intervention group started with the highest adherence
through 24 weeks and then declined to end up with the
lowest adherence at 48 weeks. The MI-CBT intervention
group was slightly higher than SC at 12 weeks, but also
declined over time to below SC. SC remained relatively
consistent throughout the study showing the least amount of
decline in adherence over time. As evidenced by the large
standard deviations, adherence varied greatly within groups.
Table 1 Demographic characteristics of the sample at baseline
Variables Treatment
SC n = 65 MI-CBT n = 70 MI-CBT/mDOT n = 69
n % or mean (SD) n % or mean (SD) n % or mean (SD)
Age—Mean (SD) 65 40.4 (8.2) 70 40.8 (9.6) 69 39.9 (10.7)
Male gender at birth (%) 50 76.9 % 50 71.4 % 55 79.7 %
Ethnicity/race Hispanic (%) 4 6.2 % 8 11.4 % 7 10.1 %
African American (%) 38 58.5 % 35 50.0 % 43 62.3 %
White (%) 21 32.3 % 22 31.4 % 22 31.9 %
Other (%) 6 9.2 % 13 18.6 % 4 5.8 %
Income \ $12,000/year (%) 40 69.0 % 44 67.7 % 41 66.1 %
Education
Less than high school degree (%) 17 26.2 % 14 20.0 % 15 21.7 %
High school graduate/GED (%) 21 32.3 % 20 28.6 % 21 30.4 %
More than high school degree (%) 27 41.5 % 36 51.4 % 33 47.8 %
Work status
Working full time/part time (%)a 17 26.2 % 23 32.9 % 20 29.0 %
On disability (%) 31 47.7 % 25 35.7 % 21 30.4 %
No income (%) 9 13.9 % 14 20.0 % 21 30.4 %
Married/committed relationship 15 23.4 % 15 21.7 % 20 29.0 %
Covered by private insurance (%) 5 7.7 % 5 7.1 % 8 11.6 %
CD4—% below 200 cells 31 47.6 % 25 36.2 % 33 47.8 %
ART Naı¨ve 21 32.3 % 24 34.3 % 24 34.8 %
Illicit drug use in last 3 months (%) 29 44.6 % 29 42.0 % 30 43.5 %
Binge drinking in last 30 days (%) 15 23.1 % 11 15.9 % 14 20.3 %
CES-D total score [16 (%) 35 53.8 % 39 56.5 % 33 47.8 %
a Categories are not mutually exclusive and three participants both worked and collected disability. Results for some baseline data for the EC
group is based on 69/70 participants as a portion of one participant’s baseline evaluation was lost during data transfer
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Post hoc ANOVA analyses comparing group means at
each individual assessment point revealed no significant
group differences, but did reveal trends for the MI-CBT/
mDOT group to have greater on-time adherence at
12 weeks [F (1, 119) = 3.67, p = .058] and worse dose
adherence at 48 weeks [F (1, 110) = 3.21, p = .076] than
the SC group.
Dose–Response Relationship
Two additional models were fit to examine the dose–
response effect of increasing intervention dose (by lowest
to highest quintiles) on non-adherence for subjects in the
MI-CBT and MI-CBT/mDOT groups while controlling for
observation period and the interaction of observation per-
iod and dose. For both outcomes, only the results of the
main effects analyses are reported as both interactions were
not significant and their inclusion did not significantly
improve model fit. Results for both percent not-taken
(Model 3) and percent not-taken on time (Model 4) showed
that while non-adherence increased over time (IRR’s
greater than 1.0), having more exposure to the intervention
was associated with less non-adherence (IRR’s less than
1.0) (Table 4). Moreover, there was a gradient effect such
that each increasing quintile of dose was predictive of a
comparable reduction in non-adherence.
Analyses of Viral Load
Table 2 displays the percentage of participants with an
undetectable VL at each assessment point by group. Across
all groups the percentage of individuals with an undetectable
Table 2 Percent adherence and clinical outcomes data by intervention arm
EDM % doses taken All participants N = 204 SC n = 65 MI-CBT n = 70 MI-CBT/mDOT n = 69
M (SD) M (SD) M (SD) M (SD)
12 weeks 78.5 (29.8) 75.3 (32.6) 77.6 (32.1) 82.5 (23.6)
24 weeks 73.0 (32.2) 73.5 (32.5) 70.9 (34.5) 74.4 (30.1)
36 weeks 70.3 (32.4) 74.7 (30.3) 69.3 (33.1) 67.2 (33.7)
48 weeks 69.6 (32.4) 75.5 (29.7) 69.3 (32.6) 64.6 (34.4)
EDM % doses taken on time
12 weeks 67.7 (31.7) 62.3 (33.6) 67.7 (32.7) 73.1 (28.2)
24 weeks 61.4 (33.1) 58.6 (33.1) 61.1 (34.4) 64.2 (32.0)
36 weeks 56.3 (33.5) 57.6 (33.2) 56.5 (34.0) 54.9 (33.8)




% (n) % (n) % (n) % (n)
Baseline 6.4 (204) 4.6 (65) 8.6 (70) 5.8 (69)
12 weeks 70.4 (159) 72.0 (50) 78.2 (55) 61.1 (54)
24 weeks 73.2 (157) 71.4 (49) 70.6 (51) 77.2 (57)
36 weeks 70.2 (121) 71.1 (38) 72.5 (40) 67.4 (43)
48 weeks 73.3 (135) 73.8 (42) 80.0 (45) 66.7 (48)
EDM electronic drug monitored
Table 3 Poisson random coefficients model: incident rate ratios for intervention group, observation period, and the group by time interaction for
the level of non-adherence
Variables: models 1 and 2 Percent not takena Percent not taken on timea
IRR 95 % CI p IRR 95 % CI p
Observation period (12 weeks reference) .990 (.974, 1.005) .195 1.000 (.989, 1.011) .967
Intervention group (SC reference) .797 (.541, 1.175) .252 .782 (.594, 1.029) .079
Interaction 1.011 (1.004, 1.018) .003 1.006 (1.001, 1.011) .015
a N for full models: 709 observations on 190 participants
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VL increased from baseline to 12 weeks and then remained
relatively constant through 48 weeks. A logistic mixed
effects regression model was fit to examine the effects of
intervention group and observation period on VL (unde-
tectable vs. detectable) over time. No significant relationship
between intervention group and the likelihood of having an
undetectable VL was observed (OR = .94, 95 %
CI = .67–1.32, p = .72). Irrespective of group, the odds of
being undetectable increased significantly over time
(OR = 1.08, 95 % CI = 1.07–1.10, p = .0001).
Discussion
The primary aim of the study was to explore the efficacy of
MI-CBT counseling combined with mDOT as compared to
MI-CBT counseling alone or SC for increasing adherence
to ART. The primary analyses revealed a significant
interaction effect indicating that adherence patterns over
time differed between the groups. The pattern of results
suggest that the MI-CBT/mDOT intervention may have
had its greatest impact at 12 weeks coinciding with the
most intensive portion of the intervention, and then
declined more steeply than SC and MI-CBT as treatment
was tapered and withdrawn. This is consistent with other
studies of behavioral counseling that observe a decline at
the conclusion of active treatment [6, 8, 16, 31]. Given the
modest magnitude of the interaction effect and the lack of
significant differences between groups at any time point, it
is also possible that neither of the intervention arms had
any true impact on adherence and the observed fluctuation
is merely a function of being part of a study (i.e., Haw-
thorne Effect) followed by regression to the mean over
time. It is also possible that adaptations made to the mDOT
protocol could have diminished the impact of the mDOT
portion of the MI-CBT/mDOT intervention. Another pos-
sibility is that after initially supporting increased adher-
ence, withdrawing this intensive intervention actually had
an iatrogenic effect and drove down adherence. We could
identify no literature support for this type of rebound effect
in MI-CBT styled interventions, however, there is some
evidence of steep declines in adherence after removal of
mDOT interventions [32].
Significant dose response relationships were observed
indicating that participants who received more dose of the
interventions had better adherence. These findings increase
our confidence that the intervention may have had an
impact on some participants’ ability to adhere. While this
finding could be attributable simply to the five mDOT
visits per week where ingestion of doses were directly
observed, nearly half of participants were on twice or thrice
a day dosing schedules meaning that they self-administered
more than half of their doses outside of mDOT visits.
These findings are more consistent with the notion that
more intervention is associated with better adherence
[11, 33–37]. Nevertheless, the lack of significant main
effect findings underscores how even intensive interven-
tions can fail to substantially improve adherence over high
quality SC.
Future research should focus on adapting established
efficacious behavioral interventions [6, 31] for use in real
world settings. The results of this study suggest that these
adjunctive interventions will likely need to be intensive and
long in duration to have positive impacts on health out-
comes. Use of technology (e.g., text messaging via cell
phones) to provide the high levels of contact provided in
established effective behavioral interventions at low cost
has shown some promise (e.g., [38]) and will be essential
for effective dissemination. Linking interventions to real-
time drops in adherence assessed remotely using EDM
devises [39] may be particularly useful and allow for
matching of intervention strength and style to patient needs
and preferences which has shown promise in the treatment
of substance abuse [40]. Research of this kind will also
assist in the identification of patients in need of the most
intensive interventions while providing easily accessible
Table 4 Poisson random coefficients model: incident rate ratios for intervention dose and observation period for the level of non-adherence for
participants in the intervention groups
Variables: models 3 and 4 Percent not takena Percent not taken on timea
IRR 95 % CI p IRR 95 % CI p
Observation period (12 weeks reference) 1.016 (1.009, 1.023) \.001 1.015 (1.010, 1.020) \.001
Intervention dose (first quintile reference)
Second quintile .318 (.110, .923) .035 .473 (.217, 1.035) .061
Third quintile .161 (.052, .494) .001 .359 (.158, .816) .014
Fourth quintile .044 (.015, .129) \.001 .129 (.058, .284) \.001
Fifth quintile .034 (.011, .100) \.001 .077 (.035, .171) \.001
a N for full models: 482 observations on 129 participants
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data for establishing the cost of sustained intervention (e.g.,
[41]).
We found no evidence of a relationship between inter-
vention group and the likelihood of having an undetectable
VL. The lack of a direct effect is consistent with recent
meta-analytic findings [16, 17]. In our study the percentage
of participants with undetectable VL rose quickly and then
remained relatively stable across all arms. The high rate of
undetectable VL in the SC arm despite consistently low
levels of adherence are consistent with research demon-
strating that modern ART is more forgiving of lower levels
of adherence [42], but likely diminished our ability to
detect any intervention effect.
Study limitations include our inclusion of individuals
without documented adherence problems which likely
reduced our ability to demonstrate the full amplitude of
intervention effects [43] and lack of baseline adherence
data. Analyses were also hampered by missing VL data and
our failure to exclude participants who had already had
undetectable VL.
In spite of these limitations, this rigorous study con-
tributes to our understanding of the impact of intensive
ART adherence interventions. Although intensive, the
interventions tested here produced a modest to null impact
on adherence. The findings highlight the need for more
effective interventions to maintain high adherence over
time. The findings of an initial uptick followed by steep
decline in adherence in the MI-CBT/mDOT intervention
arm also suggest some caution maybe warranted in using
mDOT based interventions.
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